Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Untreated or Relapsed Mantle Cell Lymphoma
NCT00030875Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2002
- Primary completion
- Jul 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by Canadian Cancer Trials Group. Started Nov 2002; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00030875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030875.